In case-control studies of screening to prevent cancer mortality, exposure is ideally defined as screening that takes place within that period prior to diagnosis during which the cancer is potentially detectable using the screening modality under study. This interval has been called the detectable preclinical period (DPP). Misspecifying the duration of the DPP can bias the results of such studies. This article quantifies the impact of incorrectly estimating the duration of the DPP or using the correct average DPP but failing to consider its variability. The authors developed a computer simulation model of disease incidence and mortality with and without screening. The authors then selected cases and controls from the generated population and compared their screening histories. The results indicate that underestimation of the duration of the DPP generally leads to greater bias than does overestimation, but in both instances the extent of the bias is modified by the relative length of the DPP and the average interscreening interval. In practice, the authors recommend that to prevent a falsely low estimate of the effectiveness of a screening test in reducing mortality, a high percentile of the DPP distribution be used when analyzing the results of case-control studies of screening. Am J Epidemiol 1998; 148:292-7.
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case-control studies; mass screening During the last 10 years, the case-control study has become an important tool for evaluating the impact of screening on cancer mortality. To date, case-control studies have addressed the effectiveness of sigmoidoscopy to detect colorectal cancer (1), of breast selfexamination to detect breast cancer (2) , of rectal examinations to detect prostate cancer (3), of cervical smears to detect cervical cancer (4) , and of skin selfexamination to detect melanoma (5) .
Attention has been given to both the methodological and the applied aspects of case-control studies of screening for cancer, in particular to appropriate definitions of cases, controls, and relevant screening history (6) (7) (8) (9) (10) . It has been recommended (6) that the cases in such a case-control study consist of persons who developed the outcome that the screening seeks to identify and prevent, commonly those persons who died of the disease. The controls should be individuals representative of the population from which the cases were selected and who were at risk for developing cancer when the cases were diagnosed. The exposure variable should consist of some summary of the screening histories of the cases and their controls prior to the date on which a case was diagnosed. These screening histories are usually obtained from medical records or interviews, and care must be taken to ensure that diagnostic tests are not classified as screening tests and vice versa. The case-control analysis estimates relative risk by dividing the odds that cases were screened by the odds that controls were screened. If a smaller proportion of cases than controls was screened, then the relative risk would be less than 1, suggesting a benefit of screening.
Weiss et al. (9) pointed out that when exposure is defined in these studies, attention should focus on screening during the detectable preclinical period (DPP). The DPP is the interval during which the disease is potentially detectable using a screen but has not yet been diagnosed clinically. Defining exposure as a history of the use of one or more screening tests during the DPP leads to an odds ratio that directly estimates the effect of screening when it is potentially protective. Since those screening tests that are performed before the DPP and produce negative results clearly are not beneficial, using them for both cases and controls can lead to an odds ratio that is spuriously close to the null value. Thus, Weiss et al. recommend against basing exposure definitions on the entire screening histories of the cases and controls. Hosek et al. (11) also note that inflation of the odds ratio can result from such a practice, since, on average, the period during which the screening behavior of controls is assessed will be shorter than that for screen-detected cases. However, Hosek et al.'s estimates of the magnitude of the bias apply to an ordinal definition of screening exposure that counts the number of screens performed for cases and controls before diagnosis. We do not address the ordinal approach in this article.
Given the potential for bias when screening histories are assessed during the entire prediagnosis period, restricting attention to the DPP is clearly desirable. Ideally, cases would be considered exposed if they were screened one or more times during an interval equal to the DPP prior to diagnosis. Similarly, screening of controls would be assessed during an analogous interval prior to diagnosis of their matched cases. If the DPP is estimated correctly for each case, and screening participation is constant in the population over time, then this approach is unbiased. An incorrect estimate of the DPP can yield biased results. As we noted above, overestimation of the duration of the DPP can lead to an inflated odds ratio. Underestimation can also lead to an odds ratio closer to 1; it may even exceed 1. To illustrate how this error can occur, consider a hypothetical study in which the true DPP of a tumor is 1 year. However, when the study results are analyzed, the DPP is severely underestimated as 1 month. The percentage of cases tabulated as screened will be little affected by this error; if a case was screened during the past year, that screen likely led to this diagnosis and so probably occurred in the previous month. However, the percentage of controls screened during the past month would be about only one twelfth that screened during the past year.
Even if the average mean length of the DPP is estimated accurately, the length of the true DPP likely will vary across cases. Thus, for many individuals, the DPP will either be overestimated or underestimated, and some attenuation of the odds ratio is to be expected.
This article explores, in case-control studies of screening and disease mortality, the impact of incorrectly estimating the length of the DPP or of using the correct average DPP duration but failing to consider its variability. We use a computer model to simulate a realistic scenario of cancer incidence, screening, and disease mortality. The model is loosely based on breast cancer data from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute (12) and a survey of mammography use among women aged 50-80 years conducted in Washington State in 1994. Data are simulated under various assumptions about screening efficacy and are analyzed using both correct and incorrect estimates of the mean duration of the DPP.
MATERIALS AND METHODS
We constructed a computer model of the disease process in a defined population and then simulated a case-control study in that population. Simulation models are appropriate for investigating the properties of analytic procedures, since the otherwise unobservable information generated by the models can be used to correctly estimate relative risk. These estimates provide a benchmark against which the results of the procedures under investigation can be compared.
The simulation model generated hypothetical medical records for a cohort of 40,000 persons. Based on data from the Surveillance, Epidemiology, and End Results Program (12), the model was assumed to be loosely representative of the breast cancer experience of women aged 50-85 years. In general, we tried to keep the model as simple as possible while still retaining features that affected the performance of the analytic procedures of interest. Incidence, diagnosis, and mortality data were generated prospectively over a period representing 35 calendar years, and subjects for the case-control study were then sampled from the resulting population. Table 1 lists the inputs required, the values we assumed, and our information sources. To summarize, 10 percent of the cohort was assigned a date of clinical cancer diagnosis. For these cases, the length of the DPP either was constant or followed a specified statistical distribution across individuals. We assumed a mean DPP of 3 years. This DPP for breast cancer is somewhat longer than that in some published estimates (13, 14) , but it is consistent with a 1997 study (15) and allowed us to demonstrate more clearly the effects of underestimating the DPP duration. The length of the DPP was independent of age at clinical diagnosis.
Once the beginning and end of the DPP had been determined for each disease case, screening in the population was modeled using information collected during the Community Mammography trial survey, which was conducted in 1994 among a sample of women in 40 predominantly rural communities in Washington State (M. R. Andersen and N. Urban, Fred Hutchinson Cancer Research Center, unpublished manuscript). Among those for whom there were complete data, 12 percent had not had a previous mammogram, 55 percent had had at least two previous mammograms with no more than a 1-to 2-year inter- val between examinations, and 33 percent had had only one previous mammogram or two previous mammograms at least 2 years apart. On the basis of these results, we defined three types of screening behavior in the population: no screening (12 percent); regular users, that is, annual screening with a probability of 0.65 (55 percent); and irregular users, that is, annual screening with a probability of 0.1 (33 percent). Note that annual screening with a probability of 0.65 or 0.1 implies that 88 percent or 19 percent of such individuals, respectively, will be screened at least once every 2 years. Thus, if these settings are assumed, approximately 54.7 percent ((0.55 X 88 percent) + (0.33 X 19 percent)) of the simulated population was screened at least once every 2 years, which is close to the results of the Community Mammography survey. Given the screening behavior of the population, it was possible to determine which cases were detected as a result of screening and which were detected clinically. Individuals who were screened during their DPP were assigned a time of diagnosis that corresponded to the date of their first screen during the DPP. Screening was assumed to be 100 percent sensitive. Individuals who were not detected by screening were detected clinically at the end of their DPP.
Disease-specific mortality figures for individuals detected clinically and by screening were generated as follows. Survival of individuals with clinically detected disease was based on data from the Surveillance, Epidemiology, and End Results Program regarding breast cancer mortality among cases aged 50 years or older who were diagnosed between 1973 and 1976. The relative estimated survival rate 15 years following diagnosis (12) (equivalently, 1 -causespecific mortality) was almost 55 percent. Thus, we assumed that 45 percent of persons with clinically detected illness died of their disease within 15 years. Data were simulated assuming no effect and a beneficial effect of screening on breast cancer mortality. Where screening is efficacious, we assumed that mammography reduced cancer mortality by one third (16); therefore, 30 percent of individuals whose illness was detected by screening died of their disease within 15 years as compared with 45 percent of cases detected clinically. For the former cases, survival was assumed from the date on which clinical detection would plausibly have occurred, to avoid including the lead time. The length of survival for individuals who died of the disease was assumed to be uniform over 15 years of follow-up. No competing causes of death were assumed, since they were not expected to have an important impact on the results.
Once the prospective population data had been generated, the cases and controls were sampled. The cases consisted of persons who died from their disease during the last 15 years of observation. One disease-free control was selected per case.
The simulation model was run using various settings of DPP duration and degrees of screening efficacy (100 simulations per setting). First, we used a constant DPP duration of 3 years and no screening efficacy, that is, a true odds ratio of 1. We then computed the odds ratios corresponding to a range of different DPP durations that might be assumed during an analysis to assess the bias resulting from incorrectly estimating DPP length. Second, the bias resulting from incorrectly estimating the DPP under screening efficacy was assessed in a similar way. Third, we assumed efficacy and varied the duration of the DPP across individuals; each was assigned an integer of 1-5 years with a probability of one fifth, leading to a distribution with a mean DPP of 3 years. Once again, we computed the odds ratios corresponding to different assumed DPP durations to see which led to the least biased result. Table 2 gives the odds ratios corresponding to the three different simulations outlined above. The columns labeled 1 and 2 show results corresponding to a constant DPP in the population. The column labeled 3 shows results corresponding to a DPP expressed as an integer of 1-5 years. Table 2 also shows the unbiased odds ratios, namely, those computed using the true DPP duration for each case. The unbiased odds ratio is the ratio of the odds of death from cancer given screening during the DPP to the odds given no screening during this time. It is approximately equal to the ratio of the case fatality rate for individuals whose disease was detected by screening to that for individuals whose disease was detected clinically, provided that the disease is relatively uncommon and that screening behavior is unrelated to disease risk. Note that the odds ratios given in table 2 are empirical rather than theoretical quantities; that is, they are estimated on the basis of a finite number of simulations. Consequently, the values shown in the table may not exactly equal their theoretical counterparts.
RESULTS
The data in table 2 confirm that both overestimation and underestimation of DPP duration led to inflation of the odds ratios, but a substantially greater bias was associated with underestimation. Under screening efficacy, for example, assuming a duration of 1 year when the true duration was 3 years led to an odds ratio of 1.69, whereas the unbiased odds ratio was only 0.67. However, assuming a duration of 5 years when the true duration was 3 years led to an odds ratio of 0.70, which is not far from the unbiased value. When the DPP varied across individuals, an analysis that used the maximum DPP of 5 years (odds ratio = 0.72) was less biased than the one that used the mean DPP of 3 years (odds ratio = 0.77). Although the mean and the maximum led to some attenuation of the odds ratio, it was not significant enough to obscure the reduced mortality risk associated with screening.
The relatively small bias present when overestimating DPP duration is partly due to the frequency of screening in the simulated population. In the simulation model, most of the screened individuals received a screen during any given 3-year period. In a sense, the population was being screened regularly every 3 years or less. When a fraction of the population is being screened regularly, all assumed DPP lengths that exceed the longest interscreening interval will yield exactly the same indicators of exposure for cases and controls. If the true DPP also exceeds the longest interscreening interval, then overestimating the DPP will yield exactly the same result as that obtained when estimating the DPP correctly. In the simulation, the interscreening interval for most screened individuals was 3 years or less; the true DPP was 3 years. Consequently, the error resulting from overestimating the DPP was small. Table 3 shows the results obtained under screening efficacy when the interval between screens is longer and the assumed DPP is shorter than the interscreening interval. The column labeled 1 uses the same constant DPP duration and screening utilization as table 2: 12 percent nonusers, 55 percent regular users, and 33 percent irregular users. The columns labeled 2 and 3 reflect the fact that individuals are screened only once during 35 years of observation. As expected, the bias when overestimating DPP duration is greater than it is given regular screening. For example, with a true DPP of 3 years and an unbiased odds ratio of 0.67, the odds ratio assuming a DPP of 5 years is 0.70 with regular screening and 0.80 when individuals are screened only once. However, as in table 2, underestimation of the DPP still produces greater bias than does overestimation.
DISCUSSION
This article assesses the impact of incorrectly estimating the DPP in a case-control study of screening efficacy. We used a simulation approach that permits comparison of the odds ratio given the correct DPP with the odds ratio obtained when the DPP is estimated. Our results suggest that underestimation of the DPP is to be avoided if possible, since it leads to the greatest bias. Consequently, the most appropriate summary measure of DPP duration is not the mean, as might be expected, but the maximal DPP or at least a high percentile of the DPP distribution. In the presence of variability across individuals regarding the preclinical duration of their cancer, the results contradict the suggestion of Weiss et al. (9) that the assumed DPP leading to the lowest odds ratio may be indicative of the true mean DPP. However, the results support thenobservation that the lowest odds ratio is probably the least biased.
Our results suggest that in the absence of any knowledge of the DPP distribution, it may be reasonable to consider all screening prior to a case's diagnosis as long as screened individuals are screened frequently. However, some knowledge of the DPP distribution is important if screening is infrequent. Several models have been developed for estimating DPP distribution (13-15, 17, 18) . Some methods are designed to be applied to data from cancer screening programs (13) (14) (15) 17) . Others are suitable for data from case-control studies (18) .
These simulation results indicate that the pattern of screening in a population bears on the bias associated with inaccurate estimation of the DPP. This conclusion affects interpretation of the odds ratio. Specifically, the odds ratio corresponding to a given DPP duration must be interpreted in light of the interscreening interval among those members of the population who undergo screening. If individuals are being screened annually, for example, then the odds ratio for an estimated DPP duration of 10 years is not interpretable as the relative risk associated with being screened once every 10 years. Rather, it is the relative risk associated with the particular pattern of screening during the prior 10-year period in this population, that is, every year. In contrast, if individuals tend to be screened no more than once every 10 years, then the relative risk can be interpreted as the benefit resulting from being screened once in 10 years.
In conclusion, since we will never know the duration of each person's DPP, our advice in practice is to use several possible values to examine possible differences among cases and controls in receipt of screening. It should be anticipated that the least amount of bias will be present when a relatively high percentile of the assumed DPP distribution is selected for analysis. While some attenuation of the odds ratio is to be expected no matter what interval is chosen, we suspect that in most circumstances use of a high percentile of the assumed DPP will not obscure to any great extent a practically important screening benefit
